The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.
An important epigenetic modification in Huntington's disease (HD) research is histone acetylation, which is regulated by histone acetyltransferase and histone deacetylase (HDAC) enzymes. HDAC inhibitors have proven effective in HD model systems, and recent work is now focused on functional diss...
Main Authors: | Haiqun Jia, Ying Wang, Charles D Morris, Vincent Jacques, Joel M Gottesfeld, James R Rusche, Elizabeth A Thomas |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4816519?pdf=render |
Similar Items
-
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease
by: Haiqun Jia, et al.
Published: (2012-05-01) -
The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease Mice
by: Katharina Hecklau, et al.
Published: (2021-02-01) -
Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
by: Xiaona Chen, et al.
Published: (2020-11-01) -
Histone Deacetylase 3 (HDAC3) Regulates Lymphatic Vascular Development
by: Palleti Janardhan, Harish P.
Published: (2018) -
Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich’s Ataxia: A New Synthetic Route
by: Joel M. Gottesfeld, et al.
Published: (2011-12-01)